» Articles » PMID: 23875016

Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancers

Overview
Journal PLoS One
Date 2013 Jul 23
PMID 23875016
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Directly comparing gene expression profiles of estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancers cannot determine whether differentially expressed genes between these two subtypes result from dysregulated expression in ER+ cancer or ER- cancer versus normal controls, and thus would miss critical information for elucidating the transcriptomic difference between the two subtypes.

Principal Findings: Using microarray datasets from TCGA, we classified the genes dysregulated in both ER+ and ER- cancers versus normal controls into two classes: (i) genes dysregulated in the same direction but to a different extent, and (ii) genes dysregulated to opposite directions, and then validated the two classes in RNA-sequencing datasets of independent cohorts. We showed that the genes dysregulated to a larger extent in ER+ cancers than in ER- cancers enriched in glycerophospholipid and polysaccharide metabolic processes, while the genes dysregulated to a larger extent in ER- cancers than in ER+ cancers enriched in cell proliferation. Phosphorylase kinase and enzymes of glycosylphosphatidylinositol (GPI) anchor biosynthesis were upregulated to a larger extent in ER+ cancers than in ER- cancers, whereas glycogen synthase and phospholipase A2 were downregulated to a larger extent in ER+ cancers than in ER- cancers. We also found that the genes oppositely dysregulated in the two subtypes significantly enriched with known cancer genes and tended to closely collaborate with the cancer genes. Furthermore, we showed the possibility that these oppositely dysregulated genes could contribute to carcinogenesis of ER+ and ER- cancers through rewiring different subpathways.

Conclusions: GPI-anchor biosynthesis and glycogenolysis were elevated and hydrolysis of phospholipids was depleted to a larger extent in ER+ cancers than in ER- cancers. Our findings indicate that the genes oppositely dysregulated in the two subtypes are potential cancer genes which could contribute to carcinogenesis of both ER+ and ER- cancers through rewiring different subpathways.

Citing Articles

3'-UTR Shortening Contributes to Subtype-Specific Cancer Growth by Breaking Stable ceRNA Crosstalk of Housekeeping Genes.

Fan Z, Kim S, Bai Y, Diergaarde B, Park H Front Bioeng Biotechnol. 2020; 8:334.

PMID: 32411683 PMC: 7201092. DOI: 10.3389/fbioe.2020.00334.


A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.

Li J, Jiang W, Liang Q, Liu G, Dai Y, Zheng H BMC Genomics. 2020; 21(1):283.

PMID: 32252627 PMC: 7132979. DOI: 10.1186/s12864-020-6659-0.


Roles of Small GTPases in Acquired Tamoxifen Resistance in MCF-7 Cells Revealed by Targeted, Quantitative Proteomic Analysis.

Huang M, Wang Y Anal Chem. 2018; 90(24):14551-14560.

PMID: 30431262 PMC: 6456261. DOI: 10.1021/acs.analchem.8b04526.


[A signature based on relative gene expression orderings for lung cancer diagnosis].

Chen Y, Zheng B, Lin Y, Zhu H, Zheng Z, Guan Q Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2018; 34(1):129-33.

PMID: 29717600 PMC: 9935376.


Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment.

Li B, Li Y, Wang X, Yan Z, Liu H, Liu G Am J Cancer Res. 2015; 5(2):726-37.

PMID: 25973310 PMC: 4396041.

References
1.
Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

2.
Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M . The KEGG resource for deciphering the genome. Nucleic Acids Res. 2003; 32(Database issue):D277-80. PMC: 308797. DOI: 10.1093/nar/gkh063. View

3.
Herschkowitz J, He X, Fan C, Perou C . The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 2008; 10(5):R75. PMC: 2614508. DOI: 10.1186/bcr2142. View

4.
Harvell D, Richer J, Singh M, Spoelstra N, Finlayson C, Borges V . Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008; 112(3):489-501. DOI: 10.1007/s10549-008-9923-6. View

5.
Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View